Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma.

Blair AB, Sorber R, Rozich NS, Burkhart RA.

Pancreas. 2019 Sep;48(8):973-984. doi: 10.1097/MPA.0000000000001376.

PMID:
31425483
2.

Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma.

Wright MJ, Overton HN, Teinor JA, Ding D, Burkhart RA, Cameron JL, He J, Wolfgang CL, Weiss MJ, Javed AA.

J Gastrointest Surg. 2019 Jul 3. doi: 10.1007/s11605-019-04311-z. [Epub ahead of print]

PMID:
31270718
3.

Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts.

Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, Wolfgang CL, Park Y, Preall J, Jaffee EM, Califano A, Robson P, Tuveson DA.

Cancer Discov. 2019 Aug;9(8):1102-1123. doi: 10.1158/2159-8290.CD-19-0094. Epub 2019 Jun 13.

PMID:
31197017
4.

Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.

Blair AB, Kim VM, Muth ST, Saung MT, Lokker N, Blouw B, Armstrong TD, Jaffee EM, Tsujikawa T, Coussens LM, He J, Burkhart RA, Wolfgang CL, Zheng L.

Clin Cancer Res. 2019 Sep 1;25(17):5351-5363. doi: 10.1158/1078-0432.CCR-18-4192. Epub 2019 Jun 11.

PMID:
31186314
5.

Missed psychosocial risk factors during routine preoperative evaluations are associated with increased complications after elective cancer surgery.

Meyers PM, Leeds IL, Enumah ZO, Burkhart RA, He J, Haut ER, Efron JE, Johnston FM.

Surgery. 2019 Aug;166(2):177-183. doi: 10.1016/j.surg.2019.04.015. Epub 2019 May 31.

PMID:
31160060
6.

Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.

Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, Debeljak M, Kamiyama H, Narang A, Laheru DA, Zheng L, Lin MT, Gocke CD, Fishman EK, Hruban RH, Goggins MG, Molenaar IQ, Cameron JL, Weiss MJ, Velculescu VE, He J, Wolfgang CL, Eshleman JR.

Clin Cancer Res. 2019 Aug 15;25(16):4973-4984. doi: 10.1158/1078-0432.CCR-19-0197. Epub 2019 May 29.

PMID:
31142500
7.

Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, Burkhart RA, Rinkes IHMB, Molenaar IQ, Cameron JL, Weiss MJ, Wolfgang CL, He J.

Ann Surg. 2019 Jun;269(6):1154-1162. doi: 10.1097/SLA.0000000000002734.

PMID:
31082915
8.

Negative Pressure Wound Therapy for Surgical-site Infections: A Randomized Trial.

Javed AA, Teinor J, Wright M, Ding D, Burkhart RA, Hundt J, Cameron JL, Makary MA, He J, Eckhauser FE, Wolfgang CL, Weiss MJ.

Ann Surg. 2019 Jun;269(6):1034-1040. doi: 10.1097/SLA.0000000000003056.

PMID:
31082899
9.

Surgical Resection of 78 Pancreatic Solid Pseudopapillary Tumors: a 30-Year Single Institutional Experience.

Wright MJ, Javed AA, Saunders T, Zhu Y, Burkhart RA, Yu J, He J, Cameron JL, Makary MA, Wolfgang CL, Weiss MJ.

J Gastrointest Surg. 2019 May 9. doi: 10.1007/s11605-019-04252-7. [Epub ahead of print]

PMID:
31073801
10.

Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer.

Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, Yu J, Borel Rinkes IHM, Molenaar IQ, Cameron JL, Weiss MJ, Wolfgang CL, He J.

Eur J Surg Oncol. 2019 Sep;45(9):1674-1683. doi: 10.1016/j.ejso.2019.04.007. Epub 2019 Apr 11.

PMID:
31023560
11.

Pancreatic Nerve Sheath Tumors: a Single Institutional Series and Systematic Review of the Literature.

Javed AA, Wright MJ, Hasanain A, Chang K, Burkhart RA, Hruban RH, Thompson E, Fishman EK, Cameron JL, He J, Wolfgang CL, Weiss MJ.

J Gastrointest Surg. 2019 Apr 2. doi: 10.1007/s11605-019-04201-4. [Epub ahead of print]

PMID:
30941687
12.

Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival.

Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, van Oosten AF, Molenaar IQ, Cameron JL, Weiss MJ, Yang SC, Wolfgang CL, He J.

HPB (Oxford). 2019 Aug;21(8):998-1008. doi: 10.1016/j.hpb.2018.12.002. Epub 2019 Feb 15.

PMID:
30777697
13.

Main Duct Dilatation Is the Best Predictor of High-grade Dysplasia or Invasion in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Del Chiaro M, Beckman R, Ateeb Z, Orsini N, Rezaee N, Manos L, Valente R, Yuan C, Ding D, Margonis GA, Yin L, Cameron JL, Makary MA, Burkhart RA, Weiss MJ, He J, Arnelo U, Yu J, Wolfgang CL.

Ann Surg. 2019 Jan 18. doi: 10.1097/SLA.0000000000003174. [Epub ahead of print]

PMID:
30672797
14.

Enhancing Patient Outcomes while Containing Costs after Complex Abdominal Operation: A Randomized Controlled Trial of the Whipple Accelerated Recovery Pathway.

Lavu H, McCall NS, Winter JM, Burkhart RA, Pucci M, Leiby BE, Yeo TP, Cannaday S, Yeo CJ.

J Am Coll Surg. 2019 Apr;228(4):415-424. doi: 10.1016/j.jamcollsurg.2018.12.032. Epub 2019 Jan 17.

PMID:
30660818
15.

Psychosocial Risks are Independently Associated with Cancer Surgery Outcomes in Medically Comorbid Patients.

Leeds IL, Meyers PM, Enumah ZO, He J, Burkhart RA, Haut ER, Efron JE, Johnston FM.

Ann Surg Oncol. 2019 Apr;26(4):936-944. doi: 10.1245/s10434-018-07136-3. Epub 2019 Jan 7.

PMID:
30617868
16.

Negative Pressure Wound Therapy for Surgical-site Infections: A Randomized Trial.

Javed AA, Teinor J, Wright M, Ding D, Burkhart RA, Hundt J, Cameron JL, Makary MA, He J, Eckhauser FE, Wolfgang CL, Weiss MJ.

Ann Surg. 2018 Oct 10. doi: 10.1097/SLA.0000000000003056. [Epub ahead of print]

PMID:
30308616
17.

Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.

Javed AA, Wright MJ, Siddique A, Blair AB, Ding D, Burkhart RA, Makary M, Cameron JL, Narang A, Herman J, Zheng L, Laheru D, Weiss MJ, Wolfgang C, He J.

J Gastrointest Surg. 2019 Jan;23(1):112-121. doi: 10.1007/s11605-018-3966-8. Epub 2018 Sep 21.

18.

Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study.

Gemenetzis G, Groot VP, Yu J, Ding D, Teinor JA, Javed AA, Wood LD, Burkhart RA, Cameron JL, Makary MA, Weiss MJ, He J, Wolfgang CL.

Ann Surg. 2018 Sep;268(3):408-420. doi: 10.1097/SLA.0000000000002925.

PMID:
30080739
19.

Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Groot VP, Gemenetzis G, Blair AB, Ding D, Javed AA, Burkhart RA, Yu J, Borel Rinkes IH, Molenaar IQ, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Wolfgang CL, He J.

Ann Surg Oncol. 2018 Aug;25(8):2475-2483. doi: 10.1245/s10434-018-6558-7. Epub 2018 Jun 14.

20.

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O'Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA.

Cancer Discov. 2018 Sep;8(9):1112-1129. doi: 10.1158/2159-8290.CD-18-0349. Epub 2018 May 31.

21.

Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.

Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Løes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ.

JAMA Surg. 2018 Jul 18;153(7):e180996. doi: 10.1001/jamasurg.2018.0996. Epub 2018 Jul 18.

22.

Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.

Burkhart RA, Baker LA, Tiriac H.

Methods Mol Biol. 2018;1787:253-261. doi: 10.1007/978-1-4939-7847-2_19.

PMID:
29736724
23.

Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.

Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, Fishman EK, Hruban RH, Yu J, Burkhart RA, Cameron JL, Weiss MJ, Wolfgang CL, He J.

Ann Surg. 2019 Aug;270(2):340-347. doi: 10.1097/SLA.0000000000002753.

PMID:
29596120
24.

Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, Burkhart RA, Rinkes IHMB, Molenaar IQ, Cameron JL, Weiss MJ, Wolfgang CL, He J.

Ann Surg. 2018 Mar 23. doi: 10.1097/SLA.0000000000002734. [Epub ahead of print]

PMID:
29578908
25.

Lessons learned from 29 lymphoepithelial cysts of the pancreas: institutional experience and review of the literature.

Groot VP, Thakker SS, Gemenetzis G, Noë M, Javed AA, Burkhart RA, Noveiry BB, Cameron JL, Weiss MJ, VandenBussche CJ, Fishman EK, Hruban RH, Wolfgang CL, Lennon AM, He J.

HPB (Oxford). 2018 Jul;20(7):612-620. doi: 10.1016/j.hpb.2018.01.003. Epub 2018 Mar 9. Review.

26.

Patient-derived organoid models help define personalized management of gastrointestinal cancer.

Aberle MR, Burkhart RA, Tiriac H, Olde Damink SWM, Dejong CHC, Tuveson DA, van Dam RM.

Br J Surg. 2018 Jan;105(2):e48-e60. doi: 10.1002/bjs.10726. Review.

27.

Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?

He J, Blair AB, Groot VP, Javed AA, Burkhart RA, Gemenetzis G, Hruban RH, Waters KM, Poling J, Zheng L, Laheru D, Herman JM, Makary MA, Weiss MJ, Cameron JL, Wolfgang CL.

Ann Surg. 2018 Jul;268(1):1-8. doi: 10.1097/SLA.0000000000002672.

28.

Long-term survival after resection of sarcomatoid carcinoma of the pancreas: an updated experience.

Blair AB, Burkhart RA, Griffin JF, Miller JA, Weiss MJ, Cameron JL, Wolfgang CL, He J.

J Surg Res. 2017 Nov;219:238-243. doi: 10.1016/j.jss.2017.05.065. Epub 2017 Jul 3.

29.

Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Burkhart RA, Pawlik TM.

Cancer Control. 2017 Jul-Sep;24(3):1073274817729235. doi: 10.1177/1073274817729235. Review.

30.

Surgical Site Infections Following Pancreaticoduodenectomy.

Burkhart RA, Weiss MJ.

HPB (Oxford). 2017 Dec;19(12):1131. doi: 10.1016/j.hpb.2017.08.006. Epub 2017 Sep 19. No abstract available.

31.

Preoperative risk factors for conversion and learning curve of minimally invasive distal pancreatectomy.

Hua Y, Javed AA, Burkhart RA, Makary MA, Weiss MJ, Wolfgang CL, He J.

Surgery. 2017 Nov;162(5):1040-1047. doi: 10.1016/j.surg.2017.07.014. Epub 2017 Sep 1.

PMID:
28866314
32.

Role of exosomes in treatment of hepatocellular carcinoma.

Moris D, Beal EW, Chakedis J, Burkhart RA, Schmidt C, Dillhoff M, Zhang X, Theocharis S, Pawlik TM.

Surg Oncol. 2017 Sep;26(3):219-228. doi: 10.1016/j.suronc.2017.04.005. Epub 2017 Apr 25. Review.

PMID:
28807240
33.

Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.

Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, Buscaglia JM, Kim EJ, Grem JL, Lazenby AJ, Grunkemeyer JA, Hollingsworth MA, Grandgenett PM, Egeblad M, Park Y, Tuveson DA, Vakoc CR.

Cell. 2017 Aug 24;170(5):875-888.e20. doi: 10.1016/j.cell.2017.07.007. Epub 2017 Jul 27.

34.

Laparoscopic hepatectomy for hepatocellular carcinoma: are oncologic outcomes truly superior to an open approach?

Moris D, Burkhart RA, Beal EW, Pawlik TM.

Hepatobiliary Surg Nutr. 2017 Jun;6(3):200-202. doi: 10.21037/hbsn.2017.03.09. No abstract available.

35.

The use of negative pressure wound therapy to prevent post-operative surgical site infections following pancreaticoduodenectomy.

Burkhart RA, Javed AA, Ronnekleiv-Kelly S, Wright MJ, Poruk KE, Eckhauser F, Makary MA, Cameron JL, Wolfgang CL, He J, Weiss MJ.

HPB (Oxford). 2017 Sep;19(9):825-831. doi: 10.1016/j.hpb.2017.05.004. Epub 2017 Jun 8.

36.

Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response.

Burkhart RA, Ronnekleiv-Kelly SM, Pawlik TM.

Surg Oncol. 2017 Jun;26(2):138-145. doi: 10.1016/j.suronc.2017.01.009. Epub 2017 Feb 21. Review.

PMID:
28577719
37.

Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.

Ronnekleiv-Kelly SM, Burkhart RA, Pawlik TM.

Surg Oncol. 2016 Sep;25(3):190-9. doi: 10.1016/j.suronc.2016.05.018. Epub 2016 May 20. Review.

38.

Laparoscopic total pancreatectomy with islet autotransplantation for chronic pancreatitis.

Blair AB, Burkhart RA, Hirose K, Makary MA.

J Vis Surg. 2016 Jul 22;2:121. doi: 10.21037/jovs.2016.07.05. eCollection 2016.

39.

Reducing colorectal surgical site infections: a novel, resident-driven, quality initiative.

Hewitt DB, Tannouri SS, Burkhart RA, Altmark R, Goldstein SD, Isenberg GA, Phillips BR, Yeo CJ, Cowan SW.

Am J Surg. 2017 Jan;213(1):36-42. doi: 10.1016/j.amjsurg.2016.04.009. Epub 2016 Jun 14.

PMID:
27427296
40.

Management of Type 9 Hepatic Arterial Anatomy at the time of Pancreaticoduodenectomy: Considerations for Preservation and Reconstruction of a Completely Replaced Common Hepatic Artery.

Hicks CW, Burkhart RA, Weiss MJ, Wolfgang CL, Cameron AM, Pawlik TM.

J Gastrointest Surg. 2016 Jul;20(7):1400-4. doi: 10.1007/s11605-016-3154-7. Epub 2016 May 2.

41.

MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.

Tholey RM, Lal S, Jimbo M, Burkhart RA, Blanco FF, Cozzitorto JA, Eisenberg JD, Jiang W, Iacobuzio-Donahue CA, Witkiewicz AK, Glbert M, Yeo CJ, Brody JR, Sawicki JA, Winter JM.

Mol Cancer Res. 2015 Mar;13(3):439-48. doi: 10.1158/1541-7786.MCR-14-0199. Epub 2014 Oct 21.

42.

Incidence and severity of pancreatogenic diabetes after pancreatic resection.

Burkhart RA, Gerber SM, Tholey RM, Lamb KM, Somasundaram A, McIntyre CA, Fradkin EC, Ashok AP, Felte RF, Mehta JM, Rosato EL, Lavu H, Jabbour SA, Yeo CJ, Winter JM.

J Gastrointest Surg. 2015 Feb;19(2):217-25. doi: 10.1007/s11605-014-2669-z. Epub 2014 Oct 15.

PMID:
25316483
43.

Grit: a marker of residents at risk for attrition?

Burkhart RA, Tholey RM, Guinto D, Yeo CJ, Chojnacki KA.

Surgery. 2014 Jun;155(6):1014-22. doi: 10.1016/j.surg.2014.01.015. Epub 2014 Feb 7.

PMID:
24856121
44.

dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.

McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR.

Cancer Biol Ther. 2014 Jun 1;15(6):688-98. doi: 10.4161/cbt.28413. Epub 2014 Mar 11.

45.

HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.

Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR.

Cancer Res. 2014 Feb 15;74(4):1128-40. doi: 10.1158/0008-5472.CAN-13-1915.

46.

Does resident experience affect outcomes in complex abdominal surgery? Pancreaticoduodenectomy as an example.

Relles DM, Burkhart RA, Pucci MJ, Sendecki J, Tholey R, Drueding R, Sauter PK, Kennedy EP, Winter JM, Lavu H, Yeo CJ.

J Gastrointest Surg. 2014 Feb;18(2):279-85; discussion 285. doi: 10.1007/s11605-013-2372-5. Epub 2013 Nov 13.

PMID:
24222321
47.

HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.

Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, Winter JM.

RNA Biol. 2013 Aug;10(8):1312-23. doi: 10.4161/rna.25274. Epub 2013 Jun 13.

48.

Targeting cell cycle and hormone receptor pathways in cancer.

Comstock CE, Augello MA, Goodwin JF, de Leeuw R, Schiewer MJ, Ostrander WF Jr, Burkhart RA, McClendon AK, McCue PA, Trabulsi EJ, Lallas CD, Gomella LG, Centenera MM, Brody JR, Butler LM, Tilley WD, Knudsen KE.

Oncogene. 2013 Nov 28;32(48):5481-91. doi: 10.1038/onc.2013.83. Epub 2013 May 27.

49.

Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.

Burkhart RA, Peng Y, Norris ZA, Tholey RM, Talbott VA, Liang Q, Ai Y, Miller K, Lal S, Cozzitorto JA, Witkiewicz AK, Yeo CJ, Gehrmann M, Napper A, Winter JM, Sawicki JA, Zhuang Z, Brody JR.

Mol Cancer Res. 2013 Aug;11(8):901-11. doi: 10.1158/1541-7786.MCR-12-0699. Epub 2013 May 21.

50.

Defining treatment and outcomes of hepaticojejunostomy failure following pancreaticoduodenectomy.

Burkhart RA, Relles D, Pineda DM, Gabale S, Sauter PK, Rosato EL, Koniaris LG, Lavu H, Kennedy EP, Yeo CJ, Winter JM.

J Gastrointest Surg. 2013 Mar;17(3):451-60. doi: 10.1007/s11605-012-2118-9. Epub 2013 Jan 5.

PMID:
23292459

Supplemental Content

Loading ...
Support Center